Book demo
> Trellis Blog <
Articles & insights to keep you updated on our latest developments
Articles & insights to keep you updated on our latest developments
Stay up-to-date with our latest platform developments.
Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers
Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers
Eylea (aflibercept) is a leading anti-VEGF (vascular endothelial growth factor) therapy indicated for retinal conditions such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), …
Eylea (aflibercept) is a leading anti-VEGF (vascular endothelial growth factor) therapy indicated for retinal conditions such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), …
Read more
Recent Posts
All Posts
Prior Auth
Specialty
Prior Auth
Keytruda (Pembrolizumab): Prior Authorization Guidelines and Utilization Overview Across Major U.S. Payers
Nov 29, 2024
Prior Auth
Lucentis (Ranibizumab) Prior Authorization Guide: Navigating Access Across Major U.S. Payers
Nov 29, 2024
Prior Auth
Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers
Nov 29, 2024
Prior Auth
Prolia (denosumab) Prior Authorization Guide: Navigating Access Across Major U.S. Payers
Nov 29, 2024
Specialty
What’s Driving Billions in Part B & D Spending? 10 Most Expensive Drugs in Medicare
Nov 29, 2024
Specialty
Specialty Drug Billing Dilemma: Is Medical or Pharmacy the Winning Move?
Nov 29, 2024
Recent Posts
All Posts
Prior Auth
Specialty
Prior Auth
Keytruda (Pembrolizumab): Prior Authorization Guidelines and Utilization Overview Across Major U.S. Payers
Nov 29, 2024
Prior Auth
Lucentis (Ranibizumab) Prior Authorization Guide: Navigating Access Across Major U.S. Payers
Nov 29, 2024
Prior Auth
Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers
Nov 29, 2024
Prior Auth
Prolia (denosumab) Prior Authorization Guide: Navigating Access Across Major U.S. Payers
Nov 29, 2024
Specialty
What’s Driving Billions in Part B & D Spending? 10 Most Expensive Drugs in Medicare
Nov 29, 2024
Specialty
Specialty Drug Billing Dilemma: Is Medical or Pharmacy the Winning Move?
Nov 29, 2024
Recent Posts
All Posts
Prior Auth
Specialty
Prior Auth
Keytruda (Pembrolizumab): Prior Authorization Guidelines and Utilization Overview Across Major U.S. Payers
Nov 29, 2024
Prior Auth
Lucentis (Ranibizumab) Prior Authorization Guide: Navigating Access Across Major U.S. Payers
Nov 29, 2024
Prior Auth
Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers
Nov 29, 2024
Prior Auth
Prolia (denosumab) Prior Authorization Guide: Navigating Access Across Major U.S. Payers
Nov 29, 2024
Specialty
What’s Driving Billions in Part B & D Spending? 10 Most Expensive Drugs in Medicare
Nov 29, 2024
Specialty
Specialty Drug Billing Dilemma: Is Medical or Pharmacy the Winning Move?
Nov 29, 2024
> Start today <
Let us take care of the MESS(y) data
Let us take care of the MESS(y) data
Click below to get access to our product and explore how Trellis can help you and your organization unlock new insights!
Book demo
Book demo
Book demo
2025 Trellis. All rights reserved.
2025 Trellis
2025 Trellis. All rights reserved.